Summary by Moomoo AI
NeuroSense Therapeutics reported significant achievements in 2024, with its lead drug PrimeC demonstrating remarkable results in Phase 2b ALS trial. The study showed PrimeC slowed disease progression by 33% over 18 months (p=0.007) and improved survival rates by 58%. The FDA has aligned on Phase 3 study design, planned for 2025 initiation, while partnership discussions continue for commercialization.The company reported reduced financial expenses, with R&D costs decreasing 21.9% to $5.7 million and G&A expenses dropping 12.5% to $4.2 million in 2024 compared to 2023. As of December 31, 2024, NeuroSense maintained a cash position of $3.4 million. The company also secured key patent protection for PrimeC until 2042 and plans early commercialization in Canada with estimated peak annual revenues of $100-150 million.
Comment(0)
Reason For Report